drugset / Trial / NCT00002393

A Study of Indinavir Taken With or Without DMP 266

NCT00002393 ↗

Phase 3 Completed 300 enrolled Dupont Merck
Parallel-groupTreatment

Summary

The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Efavirenz Other / unclassified — —
Background INDINAVIR ANHYDROUS Other / unclassified — —